Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes.
Alessandra Dei CasValentina SpigoniMonia CitoRaffaella AldigeriValentina RidolfiElisabetta MarchesiMichela MarinaEleonora DerlindatiRosalia AloeRiccardo C BonadonnaIvana ZavaroniPublished in: Cardiovascular diabetology (2017)
V exerts a long-term favorable effect on EPC and (C-term) SDF-1α levels at glucose equipoise, thereby implying a putative beneficial effect on vascular integrity. Trial registration Clinical Trials number: NCT01822548; name: Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes. Registered 28 March, 2013.